Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study

in European Journal of Endocrinology
View More View Less
  • 1 Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  • 2 Department of Community Health Sciences, University of Calgary
  • 3 Department of Surgery, University of Calgary
  • 4 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
  • 5 Alberta Precision Laboratories, Alberta Health Services, Calgary, Alberta, Canada
  • 6 Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada

Correspondence should be addressed to A A Leung; Email: aacleung@ucalgary.ca
Restricted access

Objective

Despite the significant morbidity and mortality associated with pheochromocytoma and paraganglioma, little is known about their epidemiology. The primary objective was to determine the incidence of pheochromocytoma and paraganglioma in an ethnically diverse population. A secondary objective was to develop and validate algorithms for case detection using laboratory and administrative data.

Design

Population-based cohort study in Alberta, Canada from 2012 to 2019.

Methods

Patients with pheochromocytoma or paraganglioma were identified using linked administrative databases and clinical records. Annual incidence rates per 100 000 people were calculated and stratified according to age and sex. Algorithms to identify pheochromocytoma and paraganglioma, based on laboratory and administrative data, were evaluated.

Results

A total of 239 patients with pheochromocytoma or paraganglioma (collectively with 251 tumors) were identified from a population of 5 196 368 people over a period of 7 years. The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year. The frequency of pheochromocytoma and paraganglioma increased with age and was highest in individuals aged 60–79 years (8.85 and 14.68 cases per 100 000 people per year for males and females, respectively). An algorithm based on laboratory data (metanephrine >two-fold or normetanephrine >three-fold higher than the upper limit of normal) closely approximated the true frequency of pheochromocytoma and paraganglioma with an estimated incidence of 0.54 cases per 100 000 people per year.

Conslusion

The incidence of pheochromocytoma and paraganglioma in an unselected population of western Canada was unexpectedly higher than rates reported from other areas of the world.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 181 181 181
Full Text Views 22 22 22
PDF Downloads 16 16 16
  • 1

    Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young Jr WFEndocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2014 99 19151942. (https://doi.org/10.1210/jc.2014-1498)

    • Search Google Scholar
    • Export Citation
  • 2

    Stolk RF, Bakx C, Mulder J, Timmers HJ & Lenders JW Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? Journal of Clinical Endocrinology and Metabolism 2013 98 11001106. (https://doi.org/10.1210/jc.2012-3669)

    • Search Google Scholar
    • Export Citation
  • 3

    Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, Tyrrell JB, Shen WT & Duh QY Pheochromocytoma crisis is not a surgical emergency. Journal of Clinical Endocrinology and Metabolism 2013 98 581591. (https://doi.org/10.1210/jc.2012-3020)

    • Search Google Scholar
    • Export Citation
  • 4

    Kiernan CM & Solorzano CC Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. Surgical Oncology Clinics of North America 2016 25 119138. (https://doi.org/10.1016/j.soc.2015.08.006)

    • Search Google Scholar
    • Export Citation
  • 5

    Neumann HPH, Young Jr WF & Eng C Pheochromocytoma and paraganglioma. New England Journal of Medicine 2019 381 552565. (https://doi.org/10.1056/NEJMra1806651)

    • Search Google Scholar
    • Export Citation
  • 6

    Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP & Kerstens MN Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. European Journal of Internal Medicine 2018 51 6873. (https://doi.org/10.1016/j.ejim.2018.01.015)

    • Search Google Scholar
    • Export Citation
  • 7

    Andersen GS, Toftdahl DB, Lund JO, Strandgaard S & Nielsen PE The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977–1981. Journal of Human Hypertension 1988 2 187189.

    • Search Google Scholar
    • Export Citation
  • 8

    Stenstrom G & Svardsudd K Pheochromocytoma in Sweden 1958–1981. An analysis of the National Cancer Registry Data. Acta Medica Scandinavica 1986 220 225232.

    • Search Google Scholar
    • Export Citation
  • 9

    De Graeff J & Horak BJ The incidence of phaeochromocytoma in the Netherlands. Acta Medica Scandinavica 1964 176 583593. (https://doi.org/10.1111/j.0954-6820.1964.tb00661.x)

    • Search Google Scholar
    • Export Citation
  • 10

    Fernandez-Calvet L & Garcia-Mayor RV Incidence of pheochromocytoma in South Galicia, Spain. Journal of Internal Medicine 1994 236 675677. (https://doi.org/10.1111/j.1365-2796.1994.tb00861.x)

    • Search Google Scholar
    • Export Citation
  • 11

    Beard CM, Sheps SG, Kurland LT, Carney JA & Lie JT Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clinic Proceedings 1983 58 802804.

    • Search Google Scholar
    • Export Citation
  • 12

    Quan H, Chen G, Walker RL, Wielgosz A, Dai S, Tu K, Campbell NR, Hemmelgarn BR, Hill MD & Johansen H et al. Incidence, cardiovascular complications and mortality of hypertension by sex and ethnicity. Heart 2013 99 715721. (https://doi.org/10.1136/heartjnl-2012-303152)

    • Search Google Scholar
    • Export Citation
  • 13

    Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, Hill MD, Ghali WA, McAlister FAHypertension Outcome and Surveillance Team of the Canadian Hypertension Education Programs. Validation of a case definition to define hypertension using administrative data. Hypertension 2009 54 14231428. (https://doi.org/10.1161/HYPERTENSIONAHA.109.139279)

    • Search Google Scholar
    • Export Citation
  • 14

    Weaver CG, Clement FM, Campbell NR, James MT, Klarenbach SW, Hemmelgarn BR, Tonelli M, McBrien KAAlberta Kidney Disease Network and the Interdisciplinary Chronic Disease Collaboration. Healthcare costs attributable to hypertension: Canadian population-based cohort study. Hypertension 2015 66 502508. (https://doi.org/10.1161/HYPERTENSIONAHA.115.05702)

    • Search Google Scholar
    • Export Citation
  • 15

    Hux JE, Ivis F, Flintoft V & Bica A Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002 25 512516. (https://doi.org/10.2337/diacare.25.3.512)

    • Search Google Scholar
    • Export Citation
  • 16

    Brain KL, Kay J & Shine B Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clinical Chemistry 2006 52 20602064. (https://doi.org/10.1373/clinchem.2006.070805)

    • Search Google Scholar
    • Export Citation
  • 17

    Karet FE & Brown MJ Phaeochromocytoma: diagnosis and management. Postgraduate Medical Journal 1994 70 326328. (https://doi.org/10.1136/pgmj.70.823.326)

    • Search Google Scholar
    • Export Citation
  • 18

    Baysal BE & Maher ER 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. Endocrine-Related Cancer 2015 22 T71T 82. (https://doi.org/10.1530/ERC-15-0226)

    • Search Google Scholar
    • Export Citation
  • 19

    Beard CM, Carney JA, Sheps SG, Lie JT & Kurland LT Incidence of phaeochromocytoma. Journal of Human Hypertension 1989 3 481.

  • 20

    McNeil AR, Blok BH, Koelmeyer TD, Burke MP & Hilton JM Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust. Australian and New Zealand Journal of Medicine 2000 30 648652. (https://doi.org/10.1111/j.1445-5994.2000.tb04358.x)

    • Search Google Scholar
    • Export Citation
  • 21

    Sutton MG, Sheps SG & Lie JT Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clinic Proceedings 1981 56 354360. (https://doi.org/10.1016/S0022-5347(1753807-0)

    • Search Google Scholar
    • Export Citation
  • 22

    Sarathi V Characteristics of pediatric pheochromocytoma/paraganglioma. Indian Journal of Endocrinology and Metabolism 2017 21 470474. (https://doi.org/10.4103/ijem.IJEM_558_16)

    • Search Google Scholar
    • Export Citation
  • 23

    Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR & Pacak K Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. Journal of Clinical Endocrinology and Metabolism 2003 88 26562666. (https://doi.org/10.1210/jc.2002-030005)

    • Search Google Scholar
    • Export Citation
  • 24

    Eisenhofer G & Peitzsch M Laboratory evaluation of pheochromocytoma and paraganglioma. Clinical Chemistry 2014 60 14861499. (https://doi.org/10.1373/clinchem.2014.224832)

    • Search Google Scholar
    • Export Citation
  • 25

    Eisenhofer G Screening for pheochromocytomas and paragangliomas. Current Hypertension Reports 2012 14 130137. (https://doi.org/10.1007/s11906-012-0246-y)

    • Search Google Scholar
    • Export Citation
  • 26

    Boyd J, Leung AA, Sadrzadeh HS, Pamporaki C, Pacak K, Deutschbein T, Fliedner S & Kline GA A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. European Journal of Endocrinology 2019 181 301309. (https://doi.org/10.1530/EJE-19-0176)

    • Search Google Scholar
    • Export Citation
  • 27

    Kline GA, Boyd J, Leung AA, Tang A & Sadrzadeh HM Moderate renal impairment does not preclude the accuracy of 24 hour urine normetanephrine measurements for suspected pheochromoctyoma. Clinical Endocrinology 2020 92 518524. (https://doi.org/10.1111/cen.14180)

    • Search Google Scholar
    • Export Citation
  • 28

    Kline GA, Boyd J, Leung AA, Tang A & Sadrzadeh HM Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing. Clinical Biochemistry 2020 77 2631. (https://doi.org/10.1016/j.clinbiochem.2020.01.005)

    • Search Google Scholar
    • Export Citation
  • 29

    Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, Klarenbach SW, Lewanczuk R, Manns BJ & Ronksley P et al. Methods for identifying 30 chronic conditions: application to administrative data. BMC Medical Informatics and Decision Making 2015 15 31. (https://doi.org/10.1186/s12911-015-0155-5)

    • Search Google Scholar
    • Export Citation
  • 30

    Neumann HP, Young Jr WF, Krauss T, Bayley JP, Schiavi F, Opocher G, Boedeker CC, Tirosh A, Castinetti F & Ruf J et al. 65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer 2018 25 T201T219. (https://doi.org/10.1530/ERC-18-0085)

    • Search Google Scholar
    • Export Citation